Mounjaro Injection Sites: Label, Rotation, Technique

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Mounjaro is administered as a subcutaneous injection. The FDA-approved product label specifies the acceptable injection sites, rotation practice, and what to avoid. This article reports those instructions factually from the product prescribing information and explains what your prescribing provider will walk you through at the start of therapy.

What the FDA label says about injection sites

Per the FDA-approved prescribing information for Mounjaro, subcutaneous injections are given in the abdomen, thigh, or upper arm. Each injection must go into subcutaneous tissue (the fat layer just under the skin) — not into muscle, not intravenously. The injection pen is designed to deliver the dose at a fixed depth when used correctly per the patient-instructions-for-use booklet supplied with every pen.

How to rotate injection sites

The label directs rotation of injection sites within an anatomical area (for example, moving around within the abdomen from one dose to the next) to reduce localized skin reactions. Avoid broken, tender, red, bruised, scarred, or hardened skin. Do not inject into the same exact spot on consecutive doses. Your prescribing provider covers rotation technique at the start of therapy.

What the label specifically excludes

Mounjaro is for subcutaneous use only — not intramuscular, not intravenous. Do not inject into an IV access line. Do not inject through clothing. Do not share injection pens (cross-contamination risk). Do not mix with another injectable medication in the same syringe unless your prescribing provider has specifically directed it. If the pen appears damaged, the solution is cloudy or discolored, or the pen has been exposed to extreme temperature, do not use it.

When to contact a provider about an injection-site reaction

Mild redness, itching, or a small raised area at the injection site is common and typically resolves within hours to a day. Contact your prescribing provider for: persistent or spreading redness or warmth, a lump that does not resolve, bleeding that does not stop, signs of infection (fever, worsening tenderness, pus), or any allergic reaction symptom (widespread rash, swelling of the face or throat, difficulty breathing). A severe allergic reaction warrants urgent or emergency care.

The PlexusDx note on injection training

PlexusDx Weight Management Protocols — including Semaglutide Injection and Tirzepatide Injection — include provider consultation that covers injection technique, pen handling, storage, and how to recognize injection-site reactions. Specific technique beyond the FDA label is the domain of your prescribing provider's training, not a blog article.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology underneath every decision. Take the Precision Peptide Genetic Test, or explore the protocol directly.

Frequently Asked Questions

Where should I inject Mounjaro?

Per the FDA-approved prescribing information, Mounjaro is injected subcutaneously in the abdomen, thigh, or upper arm. Rotate sites within an anatomical area each week. Avoid broken, tender, bruised, scarred, or hardened skin. Your prescribing provider covers injection technique at the start of therapy and should answer site-specific questions.

Can I inject in the same spot every time?

The FDA label directs rotation of injection sites within an anatomical area to reduce localized skin reactions. Do not inject in the exact same spot on consecutive doses. Moving around within the abdomen or alternating between thigh and abdomen is acceptable per label. Ask your prescribing provider for specific rotation guidance.

What if I hit a blood vessel or see bleeding?

A small amount of bleeding or mild bruising can happen and typically stops quickly with brief pressure. If bleeding does not stop, a large bruise develops, or you feel unwell after an injection, contact your prescribing provider. Injection is subcutaneous — not intravascular by design — but small vessels can be affected occasionally.

Does it matter which site I pick?

Per the FDA-approved label, abdomen, thigh, and upper arm are all acceptable subcutaneous sites. Absorption does vary modestly between sites in clinical pharmacology studies, but real-world outcomes are driven far more by consistent weekly dosing and rotation than by site choice. Follow your prescribing provider's guidance for your specific situation.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education